ANI Pharmaceuticals Inc. (ANIP)
ANI Pharmaceuticals Statistics
Share Statistics
ANI Pharmaceuticals has 21.76M shares outstanding. The number of shares has increased by -0.24% in one year.
| Shares Outstanding | 21.76M |
| Shares Change (YoY) | -0.24% |
| Shares Change (QoQ) | -0.06% |
| Owned by Institutions (%) | 99.32% |
| Shares Floating | 18M |
| Failed to Deliver (FTD) Shares | 19 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 2.29M, so 10.91% of the outstanding shares have been sold short.
| Short Interest | 2.29M |
| Short % of Shares Out | 10.91% |
| Short % of Float | 13.17% |
| Short Ratio (days to cover) | 8.77 |
Valuation Ratios
The PE ratio is -57.66 and the forward PE ratio is 10.64. ANI Pharmaceuticals's PEG ratio is 0.3.
| PE Ratio | -57.66 |
| Forward PE | 10.64 |
| PS Ratio | 1.74 |
| Forward PS | 1.5 |
| PB Ratio | 2.49 |
| P/FCF Ratio | 16.68 |
| PEG Ratio | 0.3 |
Enterprise Valuation
ANI Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.09B.
| EV / Earnings | -58.68 |
| EV / Sales | 1.77 |
| EV / EBITDA | 17.22 |
| EV / EBIT | 1860.93 |
| EV / FCF | 16.98 |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.74.
| Current Ratio | 2.72 |
| Quick Ratio | 2.02 |
| Debt / Equity | 0.74 |
| Total Debt / Capitalization | 42.36 |
| Cash Flow / Debt | 0.2 |
| Interest Coverage | 0.03 |
Financial Efficiency
Return on equity (ROE) is -0.04% and return on capital (ROIC) is 0.07%.
| Return on Equity (ROE) | -0.04% |
| Return on Assets (ROA) | -0.01% |
| Return on Capital (ROIC) | 0.07% |
| Revenue Per Employee | $684,923.08 |
| Profits Per Employee | $-20,648.83 |
| Employee Count | 897 |
| Asset Turnover | 0.48 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.69M |
| Effective Tax Rate | 0.17 |
Stock Price Statistics
The stock price has increased by -3.64% in the last 52 weeks. The beta is 0.63, so ANI Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.63 |
| 52-Week Price Change | -3.64% |
| 50-Day Moving Average | 59.95 |
| 200-Day Moving Average | 59.53 |
| Relative Strength Index (RSI) | 67.42 |
| Average Volume (20 Days) | 257.3K |
Income Statement
In the last 12 months, ANI Pharmaceuticals had revenue of 614.38M and earned -18.52M in profits. Earnings per share was -0.87.
| Revenue | 614.38M |
| Gross Profit | 614.38M |
| Operating Income | 584K |
| Net Income | -18.52M |
| EBITDA | 63.12M |
| EBIT | 584K |
| Earnings Per Share (EPS) | -0.87 |
Balance Sheet
The company has 144.86M in cash and 314.98M in debt, giving a net cash position of -170.12M.
| Cash & Cash Equivalents | 144.86M |
| Total Debt | 314.98M |
| Net Cash | -170.12M |
| Retained Earnings | -100.28M |
| Total Assets | 1.28B |
| Working Capital | 334M |
Cash Flow
In the last 12 months, operating cash flow was 64.02M and capital expenditures 0, giving a free cash flow of 64.02M.
| Operating Cash Flow | 64.02M |
| Capital Expenditures | 0 |
| Free Cash Flow | 64.02M |
| FCF Per Share | 3.31 |
Margins
Gross margin is 100%, with operating and profit margins of 0.1% and -3.01%.
| Gross Margin | 100% |
| Operating Margin | 0.1% |
| Pretax Margin | -3.62% |
| Profit Margin | -3.01% |
| EBITDA Margin | 10.27% |
| EBIT Margin | 0.1% |
| FCF Margin | 10.42% |
Dividends & Yields
ANIP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.3% |
| FCF Yield | 4.38% |
Analyst Forecast
The average price target for ANIP is $83, which is 23.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $83 |
| Price Target Difference | 23.6% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Jul 18, 2013. It was a backward split with a ratio of 1:6.
| Last Split Date | Jul 18, 2013 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 1.66 |
| Piotroski F-Score | 3 |